Skip to main content

Lab-made antibodies may help prevent COVID hospitalizations in high-risk patients, Mayo study finds

The findings only apply to "high-risk" patients with a mild or moderate case of COVID.

An injection of laboratory-created antibodies may help high-risk COVID-19 patients avoid hospitalization, according to a recently published Mayo Clinic study.

The world-renowned clinic detailed the findings of its observational study of monoclonal antibody treatments Monday. The study included nearly 1,400 "high-risk" patients that were infected with a mild or moderate case of COVID-19. 

But the Mayo told the Star Tribune it is not a substitute for a COVID-19 vaccine, which provides protection for a much longer period of time, and also significantly reduces the chances of contracting COVID-19 in the first place.

In the Mayo study, half received a combination dose of two monoclonal antibody drugs (casirivimab and imdevimab, both of which have FDA emergency use authorization) between December 2020 and April 2021, while the other half did not. They were all monitored afterward, with their status evaluated two, three and four weeks after treatment.

The results showed a 60%–70% relative reduction in hospitalization among the group that had received the antibodies treatment. The findings suggests that, for high-risk individuals with mild or moderate COVID, "this combination of monoclonal injections gives them a chance of a nonhospitalized recovery," said Raymund Razonable, M.D., a Mayo Clinic infectious diseases specialist and senior author of the study, in a news release. "In other words, they recover safely at home."

At 14 days, 1.3% of the treated group was in the hospital, compared to 3.3% of those who did not receive the monoclonal antibodies treatment. At 21 days, that figure hadn't changed for the treated group — but had increased to 4.2% for those who had not received the treatment.

At 28 days, 1.6% of treated participants were hospitalized, versus 4.8% of the non-treated group.

Monoclonal antibodies, the FDA explains, are lab-created proteins, made specifically to mimic an immune system response. Casirivimab and imdevimab are both designed to target the spike protein of SARS-CoV-2, with the goal of "block[ing] the virus’ attachment and entry into human cells."

Both received emergency use authorization in November of 2020. 

The treatment, from Regeneron, is often referred to as a "cocktail" and before being granted emergency use authorization was used to treat former President Donald Trump as he battled COVID-19.

Sign up: Subscribe to our BREAKING NEWS newsletters

The drug combination is not authorized for use in patients who are already hospitalized or require oxygen therapy due to COVID-19. The agency said at the time of authorization that the drug treatment "may be associated with worse clinical outcomes" for patients in those conditions.

But as a short-term treatment for high-risk patients with mild or moderate COVID symptoms, Dr. Razonable sounded optimistic.

"Our conclusion overall at this point is that monoclonal antibodies are an important option in treatment to reduce the impact of COVID-19 in high-risk patients," he said.

Next Up


1 dead, 2 with life-threatening injuries in Minnesota crash

The crash happened just after 7:30 p.m. Friday.

Image (1)

School bus carrying students plunges into river southwest of Fargo

None of the kids suffered life-threatening injuries, though some were taken to area hospitals.

Richfield High School

Richfield High School cancels weekend events after shooting

Two men were shot outside the school's football stadium

Screen Shot 2022-09-23 at 10.21.38 PM

Sound of shots, mass panic at Richfield football game streamed live on YouTube

Gunfire caused panic at a varsity football game Friday night.

J. Gordon

K-9 search leads to $36K fentanyl seizure during traffic stop

A traffic stop was made after the vehicle was seen speeding through the area.

Screen Shot 2022-09-23 at 5.20.08 PM

Gov. Walz reacts to Tuesday death of Mankato West student

The governor is a former geography teacher at the high school.

court room

Teen pleads guilty to Minneapolis carjacking, admits to others

The man was yanked out of the vehicle by witnesses before fleeing the scene.

Federal court house

Three plead guilty to roles in murder on Red Lake Reservation

The 2019 murder left another person seriously injured.


Sheriff: Heifer shot and butchered on farmer's pasture near Aitkin

Anyone with information regarding the incident is encouraged to call the Clearwater County Sheriff's Office.


Minneapolis murder suspect arrested in Wisconsin

The man has been wanted by police since the shooting happened in April.


the mayo clinic - edit

Mayo Clinic study details 'severe negative impacts' of long COVID

Most participants were under 65 and had no preexisting conditions.

Mayo clinic

Coronavirus: Mayo Clinic set to roll out antibody test next week

But it will be a while before the test is broadly available.

Screen Shot 2020-04-14 at 7.29.56 AM

Coronavirus: Mayo Clinic, U of M are now offering antibody tests

Gov. Tim Walz says he wants Minnesota to ramp up its testing before it goes back to work.

covid, vaccine

Study finds 'no serious health effects' linked to mRNA vaccines

The study monitored 6.2 million recipients of the Moderna or Pfizer vaccine.

Pixabay - doctor close-up stock

Minnesota opens COVID antibody treatment clinic in the Twin Cities

The treatment can decrease the likelihood someone will need to be hospitalized.

Mayo Belle Plaine

Mayo temporarily closes 5 clinics in southern MN amid COVID surge

The Mayo is reallocating staff to other sites as it deals with the COVID outbreak.

coronavirus, pandemic, masks

Coronavirus: Pandemic perspectives from U of M expert, Mayo doctor

A Mayo doctor says 80% of people who get the virus won't even know they have it.